RecruitingNCT07158229

Long-term Impact of NMDAR Encephalitis, Level 3

Social and Psychological Long-term Impact of NMDA Receptor Encephalitis, Level 3


Sponsor

Hospices Civils de Lyon

Enrollment

30 participants

Start Date

Nov 21, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

NMDA receptor antibody encephalitis is a rare autoimmune neurological disease of the central nervous system with an estimated incidence of 1.5 people per million per year. Patients with anti-NMDAR encephalitis experience an acute phase of the disease characterized by psychosis, memory loss, seizures, autonomic nervous system instability, or coma. Since the discovery of this disease 14 years ago by Prof. Dalmau, the clinical presentation of the acute phase has been well characterized, while the psychosocial impact of the disease remains largely unexplored. Currently, there are few cohort studies of patients that have identified persistent cognitive impairment as a factor impacting remission after the acute phase. Given the scarcity of information concerning the post-acute phase, it is therefore essential to determine the long-term social and psychological outcomes and their daily effects on the social and functional life of this severe disease. This is especially important as the patients are young, with a median age of 21 years, and may face lasting limitations potentially detrimental to their success in professional, educational, or social environments.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Patients with NMDAR encephalitis
  • Age ≥ 18 years old
  • Patient affiliated to a social security system
  • No opposition from the patient
  • Access to an internet connection and a computer

Exclusion Criteria3

  • Patients whithout NMDAR encephalitis
  • Patient under guardianship or curatorship
  • Patient with neurological disorders pre-existing encephalitis

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERQuestionnaires

Complete quality of life questionnaires focusing on fatigue, anxiety, depression, and sleep.


Locations(1)

Centre de référence des syndromes neurologies paranéoplasiques et encéphalites auto-immunes - Hôpital neurologiques Pierre WERTHEIMER - Groupement hospitalier Est - Hospices civiles de Lyon

Bron, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07158229


Related Trials